Researchers identify cell pathway in colon cancerFebruary 21, 2007CLEVELAND, OH - For the one in 18 men and women who will be diagnosed with cancer of the colon and rectum during their lifetime and over 150,000 people diagnosed on a yearly basis, today's genetic research news offers some optimism. In a study to be published in the Proceedings of the National Academy of Sciences, {PNAS Online Edition Feb. 20-23, 2007} led by Zhenghe John Wang, Ph.D., Assistant Professor, Department of Genetics at Case Western Reserve University School of Medicine and Case Comprehensive Cancer Center, researchers have identified a cell pathway which plays a critical role in the development of colon cancer. This pathway may also play a role in the development of lung and stomach cancers. Investigators say they have identified STAT3 {signal transducer and activator of transcription 3}, as a target regulated by PTPRT {Receptor Protein tyrosine phosphatase T}, which was previously identified to be mutated in colon, lung and stomach cancer patients. \\\
Case Western Reserve University | |||||||||||||||||||||
|
Related Colon Cancer Current Events and Colon Cancer News Articles Mayo Clinic physicians estimate new, tiny, super-sensitive probe could cut colon polyp removal in half Based on results of a landmark study, researchers at Mayo Clinic's Florida campus see a future in which virtual biopsies will eliminate the need to remove colon polyps that are not cancerous or will not morph into the disease. Breakthrough optical technology to assess colon cancer risk, accuracy Researchers at NorthShore University HealthSystem (NorthShore) and Northwestern University have discovered that fiber optic technology can for the very first time effectively measure blood levels in the colonic lining (mucosa) in humans, thus having potential applications for analyzing risk of colon cancer. Surgical treatment provides new option for some colorectal cancer patients Research out of Wake Forest University School of Medicine suggests that a surgical technique not traditionally used in advanced abdominal cancer may be a viable treatment option for some patients previously thought to be untreatable, offering the real possibility of extending survival for those patients. Black Americans Are At Greater Risk for Colon Polyps Black Americans have a higher occurrence of colon polyps, according to a new study. This is a significant finding considering the incidence of colon cancer among black men has increased and remained unchanged among black women during the last 20 years. Cancer-causing gut bacteria exposed Normal gut bacteria are thought to be involved in colon cancer but the exact mechanisms have remained unknown. Now, scientists from the USA have discovered that a molecule produced by a common gut bacterium activates signalling pathways that are associated with cancer cells. Brown-Assisted Trial Finds New Colorectal Screening Procedure Is Accurate and Less Invasive More patients stand to benefit from a comprehensive, less invasive method to accurately detect colorectal cancer and precancerous polyps, a multicenter study involving Brown University and institutions nationwide has found. Researchers identify cancer-causing gene in many colon cancers Demonstrating that despite the large number of cancer-causing genes already identified, many more remain to be found, scientists at Dana-Farber Cancer Institute have linked a previously unsuspected gene, CDK8, to colon cancer. '1-hit' event provides new opportunity for colon cancer prevention, say Fox Chase researchers More than 30 years ago, Alfred Knudson Jr., M.D., Ph.D., revolutionized the field of cancer genetics by showing that a person must lose both their paternal and maternal copies of a particular class of cancer-inhibiting genes, called tumor-suppressor genes, in order to develop cancer. Early stage colon cancer characterized by inactivation of gatekeeper gene The absence or inactivation of the RUNX3 gatekeeper gene paves the way for the growth and development of colon cancer, Singapore scientists report in the Sept. issue of the journal Cancer Cell. Previous studies have shown that RUNX3 plays a role in gastric, breast, lung and bladder cancers. Variation of normal protein could be key to resistance to common cancer drug Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug. More Colon Cancer Current Events and Colon Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||